Skip to Content

Relistor Approval History

  • FDA approved: Yes (First approved April 25th, 2008)
  • Brand name: Relistor
  • Generic name: methylnaltrexone bromide
  • Dosage form: Tablets and Subcutaneous Injection
  • Company: Salix Pharmaceuticals, Inc.
  • Treatment for: Constipation

Relistor (methylnaltrexone) is a peripherally acting mu-opioid receptor antagonist indicated to treat opioid-induced constipation.

Development History and FDA Approval Process for Relistor

Jul 19, 2016Approval Valeant and Progenics Announce FDA Approves Relistor Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
Apr 25, 2008Approval Progenics and Wyeth Announce FDA Has Approved Relistor
Jan 10, 2008Progenics and Wyeth Announce NDA Review Period for Subcutaneous Methylnaltrexone Extended by Three Months
May 31, 2007Progenics and Wyeth Announce FDA Has Accepted For Filing the New Drug Application for Subcutaneous Methylnaltrexone
Mar 30, 2007Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.